Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
86.66
+0.77 (+0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,336,033
Open
86.22
Bid (Size)
86.53 (1)
Ask (Size)
86.77 (4)
Prev. Close
85.89
Today's Range
85.86 - 86.88
52wk Range
60.47 - 86.88
Shares Outstanding
N/A
Dividend Yield
1.07%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
August 23, 2024
AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life...
Via
Benzinga
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Performance
YTD
+26.70%
+26.70%
1 Month
+10.37%
+10.37%
3 Month
+13.10%
+13.10%
6 Month
+31.44%
+31.44%
1 Year
+26.97%
+26.97%
More News
Read More
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
August 20, 2024
Via
Benzinga
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
August 20, 2024
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
Is NASDAQ:AZN a Suitable Choice for Quality Investing?
August 14, 2024
Via
Chartmill
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
August 16, 2024
Via
Benzinga
Exposures
Product Safety
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
August 16, 2024
From
AstraZeneca
Via
Business Wire
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
Via
Investor's Business Daily
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
August 15, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding
August 14, 2024
Via
Benzinga
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
August 14, 2024
Via
MarketBeat
Topics
ETFs
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
August 14, 2024
Via
InvestorPlace
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
August 13, 2024
Via
Benzinga
Exposures
COVID-19
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
August 13, 2024
Via
Benzinga
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
August 13, 2024
Via
Benzinga
Exposures
COVID-19
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
August 08, 2024
Via
Benzinga
Top Analyst Reports For AstraZeneca, TotalEnergies & ConocoPhillips
August 07, 2024
Via
Talk Markets
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
August 05, 2024
Via
Benzinga
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
August 04, 2024
Via
The Motley Fool
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2%
August 01, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Via
InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Via
Benzinga
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
July 29, 2024
From
AstraZeneca
Via
Business Wire
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
July 26, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.